

PATENT
Customer No. 24,950

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Tabatabaie et al.) Atty Dkt. No.: OKL010-105/00359A
)
SERIAL NO.: Not Yet Assigned)
)
FILED: Herewith)
)
FOR: PREVENTION OF INSULIN-DEPENDENT)
DIABETES OR ALLOGRAFT REJECTION BY)
INHIBITION OF CYCLOOXYGENASE-2 ACTIVITY)

jc997 U.S. PTO
09/852587
05/10/01

INFORMATION DISCLOSURE STATEMENT

BOX PATENT APPLICATION
Director - US Patent & Trademark Office
Washington, D. C. 20231

The following sections are being submitted for this Information Disclosure Statement:

1. [X] Preliminary Statements
2. [X] FORM PTO-1449 (Modified)
3. [X] Copies of Listed Information Items Accompanying this Statement
4. [X] Identification of Person(s) Making this Information Disclosure Statement

Express Mail No.: EL555989795US

Date Mailed: May 10, 2001

Section 1. Preliminary Statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose.

The filing of this supplemental information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

Section 2. Form PTO-1449 (Modified)

☒ A completed Form 1449 (Modified) is attached hereto.

☐ No Form 1449 (Modified) is attached.

Section 3. Copies of Listed Information Items Accompanying this Statement

Legible copies of all items listed in Form PTO-1449 (Modified) accompany this information disclosure statement.

Section 4. Identification of Person(s) Making this INFORMATION DISCLOSURE STATEMENT


The person making this statement is the attorney who signs below on the basis of the information:

☒ supplied by the inventor(s)

☐ supplied by an individual associated with the filing and prosecution of this application (37 C.F.R. § 1.56(c)).

☐ in the attorney's file

Respectfully submitted,



Daniel S. Hodgins, Reg. No. 31,026
HEAD, JOHNSON & KACHIGIAN
204 N. Robinson, Ste. 3030
Oklahoma City, OK 73102
(405)236-4000
(405)236-4010 fax

Attorney for Applicants

FORM PTO-1449 (Fill-A-Form 7.92) INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				U.S. DEPARTMENT OF COMMERCE Patent and Trademark Office				Attorney's Docket Number OKL010-105/00359A				Serial Number Not Yet Assigned							
Applicants: Tabatabaie et al.												Filing Date Herewith				Group			

jcs97 U.S. PTO
 09/852587
 05/10/01

U. S. PATENT DOCUMENTS																			
EXAM INIT.		PATENT NUMBER								ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE					

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION																
EXAM INIT.		DOCUMENT NUMBER								PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	Translation		
															YES	NO

EXAM INIT.		OTHER MATERIALS												
<i>(Including, Author, Title, Date, Relevant Pages, Place of Publication. **)</i>														
	AA	Tabatabaie et al., "spin Trapping Agent Phenyl N-tert-butylnitron Protects Against the Onset of Drug-Induced Insulin-Dependent Diabetes Mellitus," <u>FFBS Letters</u> , 407:148-152, 1997.												
	AB	Tabatabaie et al., "COX-2 Inhibition Prevents Insulin-Dependent Diabetes in Low-Dose Streptozotocin-Treated Mice," <u>Biochem & Biophys. Res. Com.</u> , 273:699-704, 2000.												

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant. **Place of Publication refers to name of publication in which the information was published.